The -6.89x TTM P/E is arithmetically unusable as an earnings signal, leaving P/B and P/S as the only interpretable anchors, and on both MVST prices below peers SES (1.27x book) and SLDP (0.91x book). Notably, the step-up from 6.60x trailing to 9.94x forward EV/EBITDA suggests the market is modelling declining forward EBITDA rather than simple multiple cheapness. The 3.68x P/FCF likewise warrants caution, since FCF margin swung between -25.0% and +37.5% over the last ten quarters, implying the cash multiple rests on an unstable denominator.

Operating margin — not net margin — is the honest read of earning power here, because the 79.5% net margin in 2026Q1 accompanied a -13.1% operating margin, a divergence consistent with non-operating gains rather than improved unit economics. The structural issue is that gross profit is not yet covering the fixed overhead: in 2026Q2, roughly $25.8M of gross profit sat against a heavier R&D and SG&A base, leaving -2.0% operating margin even as revenue recovered. Investors should treat the 29.5% gross margin in 2026Q2 as provisional rather than a restored run-rate, given the four-quarter dispersion between 1.0% and 37.6%.

ROIC has oscillated between -11.3% and +2.2% without establishing an upward trend, which suggests the company is not compounding returns but rather treading water around zero, well below any reasonable cost-of-capital threshold. The decomposition is telling: asset turnover has stayed flat in a narrow 0.06–0.12 band across all ten quarters, so virtually all of the ROA swing (from -10.7% to +6.4%) is attributable to net margin, not capital efficiency. Because ROE has printed both -26.2% and +14.7% inside eight quarters while turnover barely moved, the equity return is being driven by volatile margins and a shifting equity base rather than improving operating discipline.

The improvement from a 244-day cycle in 2024Q1 to 187 days in 2026Q2 is genuine but was driven mainly by DSO falling from 175 to 128 days, while DPO simultaneously shortened from 139 to 81 days, meaning Microvast is collecting faster yet also paying suppliers materially sooner — a net cash use rather than supplier-financed growth. DIO also remains elevated at 140 days in 2026Q2, so inventory still absorbs roughly five months of cost of goods before sale. Combined with asset turnover near 0.09, this implies the manufacturing base is running far below the utilization needed to convert its fixed assets into revenue, which would help explain the persistently sub-2% ROIC.

The deleveraging is real on a stock basis, but comfort should be judged on coverage rather than the D/E ratio, and coverage has printed -83.54x, -65.11x and -8.03x in three of the last six quarters, implying that operating losses, not repayment capacity, are doing the work. The reported D/EBITDA of 2202.59x in 2026Q1 is analytically meaningless because EBITDA had effectively collapsed toward zero, which itself is the more informative signal — leverage ratios become uninterpretable exactly when the business is weakest. Investors should monitor whether coverage can turn structurally positive on a sustained operating margin rather than on single-quarter non-operating swings.